Building a leading, global mRNA therapeutics company


years of mRNA research


issued patents


pending patents

Our Strategy

Translate Bio’s MRTTM platform has the potential to change the lives of people living with debilitating genetic diseases.

Our goal is to continue building a leading, global mRNA therapeutics company that capitalizes on our extensive experience with proprietary mRNA product development, delivery, manufacturing and process development. We are developing our first-in-class MRTTM product candidates in cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency that have the potential to transform these debilitating and life-threatening illnesses into manageable chronic conditions with an improved quality of life.

We plan to leverage the broad applicability of our MRT platform by developing additional MRTTM product candidates for our own pipeline. Specifically, we intend to:

  • Maintain our initial focus on genetic diseases with high unmet medical need in the lungs to utilize our platform to rapidly develop new product candidates.
  • Develop product candidates that address diseases with high unmet medical need, including diseases of the liver, eye, and CNS.

Our Partners

In June 2018, we announced a collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five infectious disease pathogens. This collaboration brings together Sanofi Pasteur’s leadership in vaccines and Translate Bio’s mRNA research and development expertise.

Let’s Talk

We’re interested in partnering with other dedicated experts to transform mRNA science into meaningful therapies